A Study of Treatment Patterns and Real-World Outcomes in IgA Nephropathy Patients in the United States

Más betegség

• Presence of systemic lupus erythematosus (SLE), lupus nephritis (LN), IgA vasculitis (IgAV), chronic liver disease, and Minimal Change Disease (MCD) with IgA deposition at any time during the study period.
  • Treatment Escalation Cohort:
• Presence of SLE, LN, IgAV, chronic liver disease, and MCD with IgA deposition at any time during the study period.

Laborértékek

• Any evidence of kidney failure as defined by estimated glomerular filtration rate (eGFR) <15 ml/min/1.73 m², International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) codes for chronic kidney disease (CKD) stage 5, Current Procedural Terminology (CPT) codes for kidney transplant or dialysis prior to RAASi initiation.
• Received any corticosteroids/mycophenolate mofetil (MMF), sodium-glucose co-transporter 2 inhibitor (SGLT2i), or IgAN branded therapies prior to the end of the 90 days of RAASi treatment.

Egyéb

• IgAN Cohort:

• IgAN Cohort:
• Renal biopsy confirming IgAN during the patient identification period.
• Age ≥18 at index. The index date was the date of first claim or biopsy.
• ≥182 days of continuous enrollment in medical and pharmacy claims before index date.
• ≥365 days of continuous enrollment in medical and pharmacy claims following (and including) index date.
  • Treatment Escalation Cohort:
• Renal biopsy confirming IgAN during the patient identification period.
• Age ≥18 at index.
• ≥182 days of continuous enrollment in medical and pharmacy claims before index date.
• ≥182 days of continuous enrollment in medical and pharmacy claims following (and including) index date.
• Evidence of treatment with a renin-angiotensin-aldosterone system inhibitor (RAASi) for > 3 months following IgAN diagnosis date.
• ≥1 urine protein creatinine ratio (UPCR) lab measurement following the index date.